|
Volumn 135, Issue 2, 2009, Pages 587-588
|
How should we treat "difficult" multidrug-resistant tuberculosis?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL;
2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE;
6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE;
BCG VACCINE;
LINEZOLID;
QUINOLINE DERIVED ANTIINFECTIVE AGENT;
TUBERCULOSTATIC AGENT;
ADULT;
CLINICAL ARTICLE;
DRUG EFFICACY;
DRUG HALF LIFE;
HUMAN;
LETTER;
MULTIDRUG RESISTANCE;
MYCOBACTERIUM TUBERCULOSIS;
NEUROTOXICITY;
PRIORITY JOURNAL;
TREATMENT DURATION;
TUBERCULOSIS;
|
EID: 60249086598
PISSN: 00123692
EISSN: 19313543
Source Type: Journal
DOI: 10.1378/chest.08-1776 Document Type: Letter |
Times cited : (4)
|
References (5)
|